deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 17-arm NCT04126200

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM5)

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5

Sponsor: GlaxoSmithKline

Conditions Multiple Myeloma
Interventions Belantamab mafodotin Dexamethasone Dostarlimab Feladilimab GSK3174998 Isatuximab Lenalidomide Nirogacestat Pomalidomide
Updated 27 times since 2019 Last updated: Nov 5, 2025 Started: Oct 7, 2019 Primary completion: Apr 17, 2025 Completion: Mar 11, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma and is currently ongoing. GlaxoSmithKline leads this study, which shows 27 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~Jun 2022 · 2 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jun 2023 · 9 months · monthly snapshot~Jun 2023 – ~Dec 2023 · 6 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

27 versions recorded

  1. Dec 2025 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Feb 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting · Phase: PHASE1/PHASE2 → PHASE2

  4. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 22 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Dec 2023 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jun 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2022 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Apr 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

  9. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE2 → PHASE1_PHASE2

  12. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  13. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  14. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  15. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  16. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  17. May 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  18. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  19. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  20. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  21. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  22. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, Greece , Atlanta, United States , Badalona, Spain , Boston, United States , Falun, Sweden , Fitzroy, Australia , Frankfurt, Germany , Gdansk, Poland , Grand Rapids, United States , Halifax, Canada and 28 more locations